treatment of RAS
C-RAF interaction
role of RAS
requirement of RAS
Kras-driven lung cancer
development of RAF
study lung cancer
clinical relevance of developing RAS interaction inhibitors
Lung adenocarcinoma
Ras Binding Domain
KRAS-induced lung tumourigenesis
frequent subtype of lung cancer
oncogenic KRAS
lung tumours maintenance
KRAS effector pathway
KRAS gene
new mouse model
allosteric inhibitors
cancer therapy
ERK cascade
MEK kinases inhibitors
leading mouse model
specific KRASG12C inhibitors
new pharmacological target
ERK proteins
MAPK inhibition
driven tumours
signalling pathway
strong inhibition
long-term inhibition
new innovative strategies
druggable target
normal physiology
normal cells
small molecules
patients
feedback loop
activating mutations
LSL-KrasG12D
LoxP
host crosstalk
Frt technologies
RBD
effects
outcome of recent studies
important insights
Cre
FLIPo
function
crucial question
advantage
p53
kinase activities
order
resistance
best
mice
research groups
investigations
moment
years
cases